Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease.
Animals
Antihypertensive Agents
/ pharmacology
Benzhydryl Compounds
/ pharmacology
Blood Pressure
/ drug effects
Diabetic Nephropathies
/ complications
Disease Models, Animal
Female
Glucosides
/ pharmacology
Hypertension
/ complications
Lisinopril
/ pharmacology
Mice
Sodium-Glucose Transporter 2 Inhibitors
/ pharmacology
Treatment Outcome
ACE inhibitor
SGLT2 inhibitor
diabetic kidney disease
glomerulosclerosis
mouse model
Journal
American journal of physiology. Renal physiology
ISSN: 1522-1466
Titre abrégé: Am J Physiol Renal Physiol
Pays: United States
ID NLM: 100901990
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
pubmed:
29
6
2021
medline:
24
9
2021
entrez:
28
6
2021
Statut:
ppublish
Résumé
Hypertension is a critical comorbidity for progression of diabetic kidney disease (DKD). To facilitate the development of novel therapeutic interventions with the potential to control disease progression, there is a need to establish translational animal models that predict treatment effects in human DKD. The present study aimed to characterize renal disease and outcomes of standard of medical care in a model of advanced DKD facilitated by adeno-associated virus (AAV)-mediated renin overexpression in uninephrectomized (UNx)
Identifiants
pubmed: 34180715
doi: 10.1152/ajprenal.00154.2021
doi:
Substances chimiques
Antihypertensive Agents
0
Benzhydryl Compounds
0
Glucosides
0
Sodium-Glucose Transporter 2 Inhibitors
0
Lisinopril
E7199S1YWR
empagliflozin
HDC1R2M35U
Banques de données
figshare
['10.6084/m9.figshare.14431229.v1']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM